Replimune Stock Plunges 34% Intraday Following FDA Briefing on RP1 Drug

Replimune (REPL) stock plunged 34% intraday on July 28, marking the largest single-day decline since April 13, following an FDA advisory committee briefing document on its experimental skin cancer drug RP1. The FDA document raised concerns about the drug's component contribution and patient population heterogeneity. An advisory committee meeting is scheduled for July 30 to further evaluate the drug's viability.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments